Recognizing and managing psychotic and mood disorders in primary care
The diagnosis and management of psychotic and mood disorders is an evolving process and an important clinical topic for primary care clinicians. Although many reports exist on the prevalence and treatment of depression in primary care, far less information is available about patients in this setting with depression accompanied by symptoms of mania or hypomania.
To facilitate a dialogue on the identification and treatment of psychotic and mood disorders, an actual patient case is presented by an expert faculty member, followed by a panel discussion in which the faculty’s collective experience lends further practical insights into the nuances of management of such patients in both inpatient and outpatient settings.
We hope the insights you glean from this exchange of practical clinical issues will enhance and confirm your own approach to diagnosing and treating patients with psychotic and mood disorders.
Full text | PDF
CME Pretest
Full CME Information and Test
Full CME Information
Take the free CME test for primary care physicians
View newsletters associated with this program
Financial Disclosures and Conflicts of Interest
According to the disclosure policy of the University of Cincinnati, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with the commercial companies related to this activity. All relevant relationships that are identified are reviewed for potential conflicts of interest. If a conflict of interest is identified, it is the responsibility of the University of Cincinnati to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The faculty has reported the following:
Dr Nasrallah reports that he is on the advisory board of Abbott, AstraZeneca, Cephalon, Janssen, Pfizer, and Vanda Pharmaceuticals; is a consultant for AstraZeneca, Janssen, Pfizer, and Vanda Pharmaceuticals; receives grants from AstraZeneca, Forest Laboratories, Janssen, Otsuka America Pharmaceutical Inc., Pfizer, Roche, and sanofi-aventis; and is on the speakers bureau of AstraZeneca, Janssen, and Pfizer.
Dr Black reports that he is a consultant for Forest Laboratories and Jazz Pharmaceuticals and receives grant(s) from Forest Laboratories.
Dr Goldberg reports that he is on the advisory board, speakers bureau, and serves as a consultant for AstraZeneca, Eli Lilly & Co, and Glaxo SmithKline.
Dr Pariser reports that he receives grants from Pfizer and is on the speakers bureau for AstraZeneca, GlaxoSmithKline, and Pfizer.
Dr Muzina reports that he is on the advisory board of AstraZeneca and Bristol-Myers Squibb; and is on the speakers bureau of AstraZeneca, Bristol- Myers Squibb, Pfizer, Sepracor, and Wyeth.
Planning committee: Kay Weigand, University of Cincinnati; and Kristen Georgi, Charles Williams, and Katherine Wandersee for Dowden Health Media have disclosed no relevant financial relationship(s) with any commercial interests.
No off-label uses of drugs or devices are discussed in this supplement.
None of the atypical antipsychotic agents have been approved in the psychosis or agitation of dementia, and the FDA has issued a class-effect black-box warning regarding the increased mortality in geriatric patients treated with atypical antipsychotics compared to those treated with placebo.
Support
Supported by an educational grant from AstraZeneca.
Acknowledgement
This CME activity was developed through the joint sponsorship of the University of Cincinnati and Dowden Health Media.
|
